ENLIVEN THERAPEUTICS INC.
NASDAQ: ELVN (Enliven Therapeutics, Inc.)
Last update: yesterday, 6:50AM49.82
1.06 (2.17%)
| Previous Close | 48.76 |
| Open | 48.76 |
| Volume | 844,241 |
| Avg. Volume (3M) | 1,378,808 |
| Market Cap | 3,559,055,104 |
| Price / Book | 7.68 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.92 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 21.07 |
| Operating Cash Flow (TTM) | -73.96 M |
| Levered Free Cash Flow (TTM) | -45.43 M |
| Return on Assets (TTM) | -21.36% |
| Return on Equity (TTM) | -31.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Enliven Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.75% |
| % Held by Institutions | 90.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2026 | 3,275,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | - | 45.96 | -860,123 | -39,531,253 |
| Aggregate Net Quantity | -860,123 | |||
| Aggregate Net Value ($) | -39,531,253 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 45.96 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 22 Jun 2026 | Sell (-) | 860,123 | 45.96 | 39,531,253 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |